Alico to Discuss Strategic Transformation Progress at the 37th Annual ROTH Conference
Management to host one-on-one meetings with investors on March 17th and 18th
FORT MYERS, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Alico, Inc. ('Alico' or the 'Company') (Nasdaq: ALCO) today announced that John Kiernan, the Company's President and Chief Executive Officer, will host one-on-one meetings with investors at the 37th Annual ROTH Conference at the Laguna Cliffs Marriott in Dana Point, California on March 17 and 18, 2025.
Management will provide an update on the execution of Alico's recently announced strategic transformation, including:
Progress on transitioning to a diversified land management company, with estimated portfolio value of $650-$750 million
Plans for monetizing select land assets, with $20 million in transactions expected to close in fiscal 2025
Development of alternative agricultural revenue streams through leasing arrangements and seasonal crops
Remaining open to opportunistic land sales for properties
About Alico
Alico, Inc. currently operates two divisions: Alico Citrus, currently one of the nation's largest citrus producers, and Land Management and Other Operations, which include land leasing and related support operations. While Alico Citrus will wind down operations after the current crop is harvested in the first half of calendar year 2025, due to environmental and financial challenges, Alico remains committed to Florida's agriculture industry, and will focus on its long-term diversified land usage and real estate development strategy. Learn more about Alico (Nasdaq: 'ALCO') at www.alicoinc.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding the Company's strategic transformation, the Company's future cash flow and cash reserves, the future use and estimated value of the Company's land holdings, the Company's ability to obtain requisite local, state, and federal approval of the development application[s] and execute on its plan to develop 'The Villages in Corkscrew Grove', the Company's expected future profitable growth, expectations for the management of certain acres by third-party caretakers, and any other statements relating to our future activities or other future events or conditions. These statements are based on our current expectations, estimates and projections about our business based, in part, on assumptions made by our management and can be identified by terms such as 'if,' 'will,' 'should,' 'expects,' 'plans,' 'hopes,' 'anticipates,' 'could,' 'intends,' 'targets,' 'projects,' 'contemplates,' 'believes,' 'estimates,' 'forecasts,' 'predicts,' 'potential' or 'continue' or the negative of these terms or other similar expressions.
These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including, but not limited to: our implementation of our planned strategic transformation; our plan to wind down our citrus production operations to focus on our long-term diversified land usage and real estate development strategy; our ability to secure necessary regulatory approvals and permits for land development projects, effectively manage and allocate resources to new business initiatives, attract and retain skilled personnel with expertise in diversified land usage and real estate development, navigate potential market fluctuations and economic conditions, maintain strong relationships with lenders and continue to satisfy covenants and conditions under current loan agreements and address potential environmental and zoning issues, and other challenges inherent in real estate development; our ability to increase our revenues from land usage and real estate development; adverse weather conditions, natural disasters and other natural conditions, including the effects of climate change and hurricanes and tropical storms; risks related to our expected significant revenue shift to real estate development and diversified farming operations; our ability to effectively perform grove management services, or to effectively manage our portfolio of groves; our relationship with Tropicana; if certain criteria are not met under one of our contracts with Tropicana, we could experience a significant reduction in revenues and cash flows; product contamination and product liability claims; water use regulations restricting our access to water; changes in immigration laws; harm to our reputation; tax risks associated with a Section 1031 Exchange; risks associated with the undertaking of one or more significant corporate transactions; the seasonality of our citrus business; fluctuations in our earnings due to market supply and prices and demand for our products; climate change, or legal, regulatory, or market measures to address climate change; Environmental, Social and Governance issues, including those related to climate change and sustainability; increases in labor, personnel and benefits costs; increases in commodity or raw product costs, such as fuel and chemical costs; transportation risks; any change or the classification or valuation methods employed by county property appraisers related to our real estate taxes; liability for the use of fertilizers, pesticides, herbicides and other potentially hazardous substances; compliance with applicable environmental laws; loss of key employees; material weaknesses and other control deficiencies relating to our internal control over financial reporting; macroeconomic conditions, such as rising inflation and the deadly conflicts in Ukraine and Israel; system security risks, data protection breaches, cybersecurity incidents and systems integration issues; our indebtedness and ability to generate sufficient cash flow to service our debt obligations; higher interest expenses as a result of variable rates of interest for our debt; our ability to continue to pay cash dividends; and certain of the other factors described under the sections "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2024 filed with the Securities and Exchange Commission (the 'SEC') on February 12, 2025. Except as required by law, we do not undertake an obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
Investor Contact:John MillsICR(646) 277-1254InvestorRelations@alicoinc.com
Brad HeineChief Financial Officer(239) 226-2000bheine@alicoinc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Asian shares mixed and oil prices stay high over Iran-Israel crisis
Asian shares were mixed and oil prices remained high on Wednesday as investors closely tracked the escalation of the conflict in the Middle East. US benchmark crude oil was down around 0.43% at $74.52 per barrel in the afternoon in Asia — or the morning in Europe. Brent crude, the international standard, slipped around 0.43% at $76.12, although both WTI and Brent remain high on the month. Crude prices rose more than 4% on Tuesday after US President Donald Trump left a Group of Seven summit in Canada early and warned that people in Iran's capital should evacuate immediately. Within about eight hours, Trump went from suggesting a nuclear deal with Iran remained 'achievable' to urging Tehran's 9.5 million residents to flee for their lives. Iran and Israel continued to exchange air strikes on Wednesday. The fighting has driven prices for crude oil and gasoline higher because Iran is a major oil exporter and it sits on the narrow Strait of Hormuz, through which much of the world's crude passes. Past conflicts in the area have caused spikes in oil prices, though they've historically proven brief after showing that they did not disrupt the flow of oil. Related Israel-Iran crisis: How vital is the Strait of Hormuz for oil market? Explosions ring out in Tehran as Israel says it struck a centrifuge site overnight Japan, meanwhile, reported that its exports fell in May as the auto industry was hit by Trump's higher tariffs, with exports to the US falling more than 11%. But Tokyo's Nikkei 225 jumped 0.78% to 38,837.48. Hong Kong's Hang Seng dropped 1.17% to 23,698.65 while the Shanghai Composite Index rose 0.3% to 3,388.77. The Kospi in Seoul gained 0.54% to 2,966.20 while Australia's S&P/ASX 200 shed 0.1% to 8,533.10. On Tuesday, US stocks slumped under the weight of higher oil prices and weaker than expected retail sales in May. Trump raised the temperature on Israel's fight with Iran by calling for 'Unconditional surrender!' on his social media platform and saying, 'We are not going to' kill Iran's leader, 'at least for now'. The S&P 500 fell 0.84% to 5,982.72 and the Dow Jones Industrial Average dropped 0.7% to 42,215.80. The Nasdaq composite fell 0.91% to 19,521.09. On early Wednesday morning in the US, S&P futures rose 0.11% to 5,991.50, Dow Jones futures increased less than 1% to 42,245.00, while Nasdaq futures advanced by 0.13% to 21,759.00. The markets will be looking to the Federal Reserve as it makes a decision on its interest rates today. The nearly unanimous expectation among traders and economists is that the Fed will make no move. In currency trading early on Wednesday, the US dollar fell 0.2% to 144.94 Japanese yen. The euro edged 0.18% higher, to $1.1502.
Business Wire
2 hours ago
- Business Wire
Faraday Future to Present at the Global Capital Network Investor Conference in Newport Beach on June 19, 2025
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ('Faraday Future', 'FF' or 'Company'), a California-based global shared intelligent electric mobility ecosystem company, announced today that its Global President, Jerry Wang, will represent the company at the upcoming Global Capital Network (GCN) Investor Conference, taking place on June 19, 2025, at the Marriott Renaissance Newport Beach Hotel. The GCN Investor Conference brings together more than 400 entrepreneurs, startups, private equity firms, venture capitalists, angel investors, and family offices for a full day of dealmaking, networking, and high-impact exposure. Jerry Wang will participate in a featured segment on the event's main stage, delivering a presentation followed by investor Q&A session. His presentation time will be at 3:27pm PT on June 19. A link to the meeting can be accessed here: Jerry Wang is expected to highlight Faraday Future's AI-driven mobility solutions, update the latest progress under the FX brand, and share strategic priorities and initiatives planned for 2025. The session will be broadcast live to GCN's global investor network via Zoom. As part of GCN's official media programming, Jerry Wang will also appear in a Press Wall interview, which will be filmed and published across the GCN's digital channels, including its YouTube platform. In addition to the speaking engagements, Faraday Future will host a full-day information booth and product showcase, offering attendees a firsthand look at FF 91 2.0. Guests will also have the opportunity to experience a test ride of the FF 91 on-site. 'We're excited to join the GCN community and introduce both FF 91 2.0 and FX Super One to a highly engaged audience of investors and industry leaders,' said Jerry Wang, Global President of Faraday Future. 'The conference offers a valuable platform to share our progress, build new relationships, and demonstrate the innovation and product quality that define our team's work.' The Global Capital Network Investor Conference is recognized for connecting high-growth companies with accredited investors through curated presentations, private meetings, and interactive product experiences. For more information about the conference, visit here. ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF 91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit FORWARD LOOKING STATEMENTS This press release includes 'forward looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'plan to,' 'can,' 'will,' 'should,' 'future,' 'potential,' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding plans and projections for the FX brand, including by not limited to the planned Super One, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: the ability to convert pre-orders into sales, none of which are binding; market demand for MPVs and MPV rentals; the Company's ability to secure the necessary funding to execute on its AI, EREV and Faraday X (FX) strategies, each of which will be substantial; the Company's ability to design and develop EREV technology; the Company's ability to design and develop AI-based solutions; competition in the AI and EREV areas, where actual or potential competitors have or are likely to have substantial advantages relative to the Company, including but not limited to experience, expertise, funding, infrastructure and personnel; the ability of the Company to execute across multiple concurrent strategies, including the UAE, bridge strategy, or FX, EREV, AI, and US geographic expansion; the Company's ability to secure necessary agreements to license third-party range extender technology and/or license or produce FX vehicles in the U.S., the Middle East, or elsewhere, none of which have been secured; the Company's ability to homologate FX vehicles for sale in the U.S., the Middle East, or elsewhere; and the Company's ability to secure necessary permits at its Hanford, CA production facility; the potential impact of tariff policy; the Company's ability to continue as a going concern and improve its liquidity and financial position; the Company's ability to pay its outstanding obligations; the Company's ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company's limited operating history and the significant barriers to growth it faces; the Company's history of losses and expectation of continued losses; the success of the Company's payroll expense reduction plan; the Company's ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company's estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company's vehicles; the Company's ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company's vehicles; current and potential litigation involving the Company; the Company's ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company's indebtedness; the Company's ability to use its 'at-the-market' program; insurance coverage; general economic and market conditions impacting demand for the Company's products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company's control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company's operations in China; the success of the Company's remedial measures taken in response to the Special Committee findings; the Company's dependence on its suppliers and contract manufacturer; the Company's ability to develop and protect its technologies; the Company's ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company's stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC.
Yahoo
3 hours ago
- Yahoo
Biomea Fusion Announces Pricing of Public Offering of Securities
REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea') (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19,450,000 shares of its common stock and accompanying warrants to purchase an aggregate of 19,450,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 550,000 shares of its common stock and accompanying warrants to purchase an aggregate of 550,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.0001 per pre-funded warrant. In addition, Biomea has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock and/or warrants at the public offering price, less underwriting discounts and commissions. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $2.50 per share, is immediately exercisable from the date of issuance and will expire eighteen months from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $2.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $1.9999. All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Biomea. The gross proceeds to Biomea from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $40 million, excluding any exercise of the underwriters' option to purchase additional shares and/or warrants. The offering is expected to close on June 20, 2025, subject to the satisfaction of customary closing conditions. Jefferies is acting as sole book-running manager for the offering The shares of common stock, pre-funded warrants and common stock warrants and shares of common stock issuable upon the exercise of the pre-funded warrants and common stock warrants are being offered by Biomea pursuant to an effective shelf registration statement on Form S-3 (File No. 333-267884), that was previously filed with the U.S. Securities and Exchange Commission ('SEC') on October 14, 2022 and declared effective on October 24, 2022. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on June 17, 2025 and is available for free on the SEC's website located at The final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available for free on the SEC's website located at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from: Jefferies LLC by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@ or by accessing the SEC's website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. Visit us at and follow us on LinkedIn, X and Facebook. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Biomea's beliefs and expectations regarding the anticipated public offering; uncertainties related to market conditions and statements regarding timing, size and expected proceeds of the proposed offering, and Biomea's research, development and regulatory plans, the progress of ongoing and upcoming clinical trials and the timing of such events. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to completion of the public offering on the anticipated terms, or at all, market conditions and statements regarding the expected gross proceeds of the offering, timing of closing of the offering, the satisfaction of customary closing conditions related to the offering and sale of securities and Biomea's ability to complete the offering. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Biomea's most recent annual report on Form 10-K filed on March 31, 2025 and subsequent quarterly reports on Form 10-Q, filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Biomea's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering filed with the SEC. Any forward-looking statements contained in this press release represent Biomea's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Biomea explicitly disclaims any obligation to update any forward-looking statements, except as required by law. Contact:Meichiel Jennifer WeissSr. Director, Investor Relations and Corporate DevelopmentIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
